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Health Care
to 24 hours after a bite, as well as removal of
any first aid such as pressure bandages with
immobilisation (PBI). This practice has
some support from anecdotal case reports of
delayed envenoming, but has never been
formally tested in snakebite cases.4-8
According to one study from southern
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MainMABSTRACT
Objectives: To determine which laboratory tests are first associated with severe 
envenoming after a snakebite, when (ie, how long after the bite) the test results become 
abnormal, and whether this can determine a safe observation period after suspected 
snakebite.
gn, patients and setting: Prospective cohort study of 478 patients with suspected 
nfirmed snakebite recruited to the Australian Snakebite Project from January 2002 
ril 2009, who had at least three sets of laboratory test results and at least 12 hours 
servation in hospital after the bite. Severe envenoming was defined as venom-
ed consumption coagulopathy (VICC), myotoxicity, neurotoxicity or thrombotic 
angiopathy.
 outcome measures: International normalised ratio (INR), activated partial 
thromboplastin time (aPTT), creatine kinase (CK) level, and neurological examination.
Results: There were 240 patients with severe envenoming, 75 with minor envenoming 
and 163 non-envenomed patients. Of 206 patients with VICC, 178 had an INR > 1.2 
(abnormal) on admission, and the remaining 28 had an INR > 1.2 within 12 hours of the 
bite. Of 33 patients with myotoxicity, a combination of CK > 250 U/L and an abnormal 
aPTT identified all but two cases by 12 hours; one of these two was identified within 12 
hours by leukocytosis. Nine cases of isolated neurotoxicity had a median time of onset 
after the bite of 4 hours (range, 35 min – 12 h). The combination of serial INR, aPTT and 
CK tests and repeated neurological examination identified 213 of 222 severe 
envenoming cases (96%) by 6 hours and 238 of 240 (99%) by 12 hours.
Conclusion: Laboratory parameters (INR, aPTT and CK) and neurological reassessments 
identified nearly all severe envenoming cases within 12 hours of the bite, even in this 
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conservative analysis that assumed normal test results if the test was not done.he
Au
wiT  majority of patients presenting tostralian emergency departmentsth suspected snakebite do not
develop envenoming.1-3 The accepted policy
in Australia is for patients to be observed
and have serial blood samples tested for up
Queensland, some hospitals discharge
asymptomatic patients with normal blood
test results 4 to 6 hours after the bite.
However, the study included only 34 enven-
omed patients, and there are concerns about
its applicability to other geographical
regions.9
No Australian study has systematically
examined the changes in early laboratory
test results observed in envenomed or non-
envenomed patients after snakebite. Some
early blood test results may be indicative of
severe envenoming and therefore useful to
determine if envenoming has occurred. Our
aim was to determine which laboratory tests
are first associated with severe envenoming
after a snakebite, when (ie, how long after
the bite) the test results become abnormal,
and whether this information might assist in
determining a safe observation period after
suspected snakebite.
METHODS
Setting and study design
This was a cohort study of patients with
confirmed or suspected snakebite recruited
to the Australian Snakebite Project (ASP).
ASP recruitment and data collection pro-
cesses have previously been described in
detail.10-12 In brief, ASP is a national, pro-
spective, multicentre study that recruits
adults and children (aged > 2 years) with
suspected or definite snakebite from over
100 hospitals. All patients have demo-
graphic and clinical information, laboratory
test results and treatments recorded on a
clinical research form, which is then entered
into a purpose-built relational database.
Ethics approval has been obtained from 19
human research ethics committees covering
all institutions involved in the study.
Study participants
Patients recruited to ASP from January 2002
to April 2009 were included in this study if
at least three sets of laboratory test results
were available and the patient was observed
in hospital for at least 12 hours after the bite
or was admitted to hospital with envenom-
ing. We compared envenomed and non-
envenomed patients, using cases classified
as severe envenoming, minor envenoming
or non-envenomed.
Severe envenoming was defined as any of
the following:
• Venom-induced consumption coagulo-
pathy (VICC): evidence of a complete con-
sumption coagulopathy, indicated by either
an undetectable fibrinogen level or a raised
D-dimer level (at least 10 times the assay
cut-off or > 2.5 mg/L), with an international
normalised ratio (INR) > 3.0.
• Myotoxicity: a creatine kinase (CK) level
> 1000 U/L, with myalgia and/or muscle
tenderness.
• Neurotoxicity: with either two nerve
groups (eg, ocular and bulbar) involved,
respiratory muscle paralysis, or requirement
for intubation or mechanical ventilation.
• Thrombotic microangiopathy: defined as
the presence of intravascular haemolysis on
the blood film, thrombocytopenia and an
abnormal creatinine level with or without
acute renal failure.13
Patients with minor envenoming were
those with evidence of envenoming but in
whom specific treatment or antivenom were
rarely required. This included patients with
isolated systemic symptoms (at least three of
nausea, vomiting, abdominal pain, diar-
rhoea, diaphoresis and headache), anticoag-
ulant coagulopathy, mild or partial VICCJA • Volume 193 Number 5 • 6 September 2010 285
HEALTH CAR E(incomplete consumption coagulopathy
characterised by low but detectable fibrino-
gen level, elevated D-dimer level and a
maximum INR < 3.0), mild neurotoxicity or
myotoxicity not meeting the criteria for
severe envenoming.
Non-envenomed patients were those who
did not manifest any of these clinical or
laboratory features of minor or severe
envenoming during their hospital stay of at
least 12 hours and did not re-present to the
hospital with delayed envenoming.
Data collection
Information was extracted from the ASP
database on: patient demographics; clini-
cal features of envenoming (including
time of onset after bite and type of neuro-
logical effects); and laboratory test results,
including a full blood count, biochemis-
try, coagulation studies (INR, activated
partial thromboplastin time [aPTT], D-
dimer and fibrinogen concentrations), and
CK level.
Analysis of diagnostic utility of early 
laboratory test results
Based on biological plausibility and visual
inspection of early serial laboratory test
results comparing patients with severe or
minor envenoming to non-envenomed
patients, only early changes in coagulation
test results, CK level, white cell count
(WCC) and lymphocyte count were fur-
ther analysed for diagnostic utility. The
cut-off values used to define abnormal
results were: INR > 1.2, aPTT outside the
reference range (depending on the indi-
vidual laboratory), CK > 250 U/L, and
WCC > 11.0  109/L. Based on previous
concerns about cases of isolated neurotox-
icity occurring in death adder envenom-
ing,9 we included a neurological exam-
ination in cases of neurotoxicity as part of
the analysis.
The primary analysis was of the time from
the bite to development of abnormal labora-
tory test result(s) or neurological examina-
tion in patients with severe or minor
envenoming, with the conservative assump-
tion that test results were normal if the test
was not done (last observation carried for-
ward). For this analysis, we plotted the
proportion of envenomed patients who still
had normal laboratory test results or neuro-
logical examination by time of the test after
the snakebite. We then used these plots to
estimate the median time until an abnormal
laboratory test result or neurological exami-
nation occurred.
1 Inclusion of patients in the study, and numbers with severe, minor and no 
envenoming
ASP = Australian Snakebite Project. VICC = venom-induced consumption coagulopathy. * Some patients had 
more than one severe envenoming syndrome, making the sum of the individual syndromes greater than the 
total number of patients with severe envenoming. ◆
719 recruited to ASP
478 included
163 not envenomed 315 envenomed
240 severe envenoming:*
VICC: 206
Myotoxicity: 33
Neurotoxicity: 17
Thrombotic microangiopathy: 20
75 minor envenoming
241 excluded
< 12 h admission: 195
< 3 sets of blood tests: 8
Presented > 12 h: 37
2 Demographic details of snakebite patients*
Not envenomed 
(n = 163)
Minor envenoming 
(n = 75)
Severe envenoming 
(n = 240)
Age in years, median 
(IQR; range)
36 (22–50; 1–83) 38 (21–56; 2–83) 41 (25–53; 1–87)
Sex (male) 107 (66%) 53 (71%) 183 (76%)
State or territory
New South Wales 38 (23%) 39 (52%) 62 (26%)
Queensland 45 (28%) 16 (21%) 68 (28%)
Western Australia 59 (36%) 9 (12%) 51 (21%)
Victoria 5 (3%) 4 (5%) 25 (10%)
South Australia 8 (5%) 1 (1%) 11 (5%)
Northern Territory 7 (4%) 5 (7%) 17 (7%)
Other 1 (1%) 1 (1%) 6 (3%)
Bite site (if known)
Upper limb 62 (38%) 31 (41%) 107 (45%)
Lower limb 75 (46%) 40 (53%) 121 (50%)
Snake type†
Brown snake 13 (8%) 12 (16%) 116 (48%)
Mulga or Collett’s snake 4 (2%) 9 (12%) 11 (5%)
Death adder 4 (2%) 2 (3%) 10 (4%)
Red-bellied black snake 8 (5%) 35 (47%) 4 (2%)
Tiger snake group 3 (2%) 8 (11%) 79 (33%)
Taipan 1 (1%) 4 (5%) 11 (5%)
Other species 11 (7%) 0 1 (0.4%)
Unknown 119 (73%) 5 (7%) 8 (3%)
PBI 111 (68%) 55 (73%) 204 (85%)
Antivenom 14 (9%) 44 (59%) 238 (99%)
Snake handler 9 (6%) 11 (15%) 36 (15%)
IQR = interquartile range. PBI = pressure bandages with immobilisation. * Figures are number (%) unless 
otherwise indicated. † Determined by a combination of expert snake identification, geographical distribution, 
clinical spectrum of effects, and venom detection in serum when available. ◆286 MJA • Volume 193 Number 5 • 6 September 2010
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to development of each abnormal laboratory
test result (INR, aPTT, CK and WCC) or
neurological examination was estimated for
individual envenoming syndromes (VICC,
myotoxicity and neurotoxicity). For exam-
ple, the time to development of an abnormal
INR was estimated for patients who devel-
oped VICC.
The final analysis was done using three of
the above tests — INR, aPTT and CK —
plus repeated neurological examination
within 6 and 12 hours, to determine if
severe envenoming could be excluded by
normal laboratory test results occurring at
these times. A similar analysis was done to
determine if minor envenoming could be
excluded with the same combination of
repeat tests and neurological examination.
For descriptive statistics, median and
range, interquartile range (IQR) or 95%
confidence intervals were used for data that
were not normally distributed. Statistical
and graphical analyses were performed
using GraphPad Prism version 5.03 for
Windows (GraphPad Software, San Diego,
Calif, USA).
RESULTS
There were 478 patients in three groups:
240 had severe envenoming, 75 had minor
envenoming and 163 were not envenomed
(Box 1, Box 2). PBI were used on 370
patients (77%) at some time.
Venom-induced consumption 
coagulopathy
VICC occurred in 206 patients, including
174 who had VICC alone and 16 who had
VICC with thrombotic microangiopathy.
The remainder had VICC with either neuro-
toxicity (6) or myotoxicity (8), or both (2).
In 178 of the 206 patients (86%), the INR
was abnormal (> 1.2) on the first set of tests
using blood samples taken a median of 1
hour and 36 minutes after the bite (range,
20 min – 11 h 30 min) (Box 3). The remain-
ing 28 patients had a normal INR recorded
before VICC developed (including one
patient who had a second normal INR at 3
hours and 45 minutes after the bite). For
these 28 patients, the median time after the
bite to the normal INR was 1 hour (range,
7 min – 3 h 45 min) and the median time
after the bite to the first abnormal INR was 4
hours and 17 minutes (range, 1 h 55 min –
10 h 30 min). In seven patients where the
time from the bite to the first abnormal INR
was greater than 6 hours, this reflected a
delay of 4 or more hours between the first
(normal) INR and the second (abnormal)
INR. For all patients with VICC, the median
time to an abnormal INR was 1.8 hours
(range, 20 min – 11 h 30 min) (Box 4, A).
Of the 28 patients whose first INR was
normal, 22 had other parameters measured
at the same time: 12 of these had an abnor-
mal D-dimer (> assay cut-off) or low fibrino-
gen (< 1.5 g/L) level. Twenty-five of the 28
patients (89%) with an initial normal INR
had PBI at the time, compared with 149 of
the 178 patients (84%) whose first INR was
abnormal despite PBI. The relative risk for
an initial normal INR with PBI was 0.65
(95% CI, 0.21–2.00; P = 0.58).
Of 31 patients with partial VICC, 26 had
an abnormal INR within 12 hours. Of the
remaining five, two had an abnormal aPTT
within 12 hours; one had myotoxicity with
CK > 250 U/L within 12 hours; and two
never had an abnormal INR, and identifica-
tion of their partial VICC was based on a
low fibrinogen or high D-dimer level.
There were 20 patients with thrombotic
microangiopathy, and all had preceding evi-
dence of VICC, with an abnormal INR
within 12 hours. Seventeen of these patients
had VICC and three had partial VICC.
Myotoxicity
Myotoxicity occurred in 33 patients with
severe envenoming who were bitten by
mulga snakes (Pseudechis australis) (8), red-
bellied black snakes (Pseudechis porphyriacus)
(4), Collett’s snake (Pseudechis colletti) (3),
snakes of the tiger snake group (Notechis spp,
Tropidechis carinatus) (14), taipans (Oxyuranus
scutellatus) (2), a death adder (Acanthophis
praelongus) (1) and a sea snake (1).
The median maximum CK level was
5390 U/L (range, 1054–203 110 U/L) in
patients with myotoxicity. An abnormal CK
level had occurred in 10 of the 33 patients
(30%) at 6 hours and in 24 patients (73%)
at 12 hours. An abnormal aPTT had
occurred in 20 patients (61%) at 6 hours
and in 25 patients (76%) at 12 hours.
Two patients with myotoxicity did not
have an abnormal CK level or aPTT within
12 hours (Box 3). One of these patients had
a normal CK level but an elevated WCC at
2 hours and 15 minutes, and the next sam-
3 Application of three laboratory tests (INR, aPTT and CK) and a neurological 
examination, and identification of patients with severe envenoming by 
abnormal test results within 12 hours of snakebite*
VICC = venom-induced consumption coagulopathy. TM = thrombotic microangiopathy. INR = international 
normalised ratio. aPTT = activated partial thromboplastin time. CK = creatine kinase. WCC = white cell count. 
* Shaded boxes represent the two cases not identified by this combination of tests within 12 hours (see text). 
† Pseudechis spp. ‡ Myotoxicity in the absence of coagulopathy. ◆
VICC: 206
Clinical syndrome Blood test abnormality Time after bite to ﬁrst 
abnormal result, median (range)
Se
ve
re
 e
nv
en
o
m
in
g
: 2
40
First INR > 1.2: 178 1 h 36 min (20 min – 11 h 30 min)
First INR  1.2: 28 4 h 17 min (1 h 55 min – 10 h 30 min)
Mild VICC
Myotoxicity: 4; TM: 2 First INR > 1.2: 6 5 h 37 min (1 h 10 min – 11 h 45 min)
Myotoxicity, black snakes:† 14
Abnormal aPTT: 12 2 h 34 min (45 min – 9 h 18 min)
CK > 250 U/L: 2 5 h 30 min, 9 h 54 min
CK > 250 U/L: 3 8 h 40 min, 9 h 6 min, 9 h 48 min
Other myotoxicity:‡ 5 WCC > 11 x 109/L: 1 2 h 15 min
All normal up to 12 h: 1
Isolated neurotoxicity: 9
Onset of ptosis or 
bulbar signs within 12 h 4 h (35 min – 12 h)MJA • Volume 193 Number 5 • 6 September 2010 287
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minutes after the bite, which then had a CK
level of 4770 U/L. The second patient had a
CK level of 220 U/L at 4 hours and no
further testing until 20 hours after the bite,
with a CK level in that sample of 691 U/L.
This patient developed myotoxicity with
localised myalgia and a CK level peaking at
12 028 U/L at 46 hours after the bite, with
ptosis and diplopia but no VICC.
For patients with myotoxicity, the median
time to an abnormal CK level was 9.1 hours
(range, 45 min – 33 h 30 min), and median
time to an abnormal aPTT was 4.2 hours
(range, 45 min – 9 h 30 min) (Box 4, A).
Of 120 non-envenomed patients who had
their CK level measured in the first 6 hours,
18 (15%) had an abnormal CK level. Of
these 18, the CK level decreased on the next
blood test for 13, and on the second subse-
quent blood test for three. It was not re-
tested for two patients. This compared with
an increase in CK level on the next blood
test in all cases of myotoxicity.
Isolated neurotoxicity
There were nine cases of isolated severe
neurotoxicity, and all nine were from death
adder bites. The median time of onset of
neurotoxicity after the bite was 4 hours
(range, 35 min – 12 h) (Box 4, A). Eight
patients had ptosis, and the ninth had bul-
bar weakness. Three patients who devel-
oped respiratory muscle paralysis and
required mechanical ventilation had evi-
dence of neurotoxicity after 35 minutes, 3
hours, and 4 hours, respectively.
Leukocytosis
An abnormal WCC developed in 192 of the
240 patients with severe envenoming
(80%), and the median time to an abnormal
WCC in these patients was 5.7 hours (range,
30 min – 26 h 45 min) (Box 4, A). Leukocy-
tosis occurred in similar numbers of mildly
and severely envenomed patients, and only
identified one case of severe envenoming
not identified by the other three tests within
12 hours in this study (Box 3). Patients with
brown snake (Pseudonaja spp) bites were
less likely to have leukocytosis occur at any
time, compared with patients with bites
from the tiger snake group (Notechis spp and
T. carinatus) or red-bellied black snakes (P.
porphyriacus).
Proposed algorithm
Using a combination of three laboratory
tests (INR, aPTT and CK) and repeated
neurological examination, 238 of the 240
patients with severe envenoming (99%) had
an abnormal laboratory test result or evi-
dence of neurotoxicity by 12 hours (Box 3
and Box 4, B). Both patients who did not
have abnormal test results within 12 hours
had myotoxicity and did not have laboratory
tests performed at 6 or 12 hours, when it
was likely their CK levels would have been
elevated. There were 222 patients with
severe envenoming who presented within 6
hours of the bite, and 213 of these (96%)
had documented abnormal laboratory test
results at 6 hours. Applying the same labora-
tory criteria to the minor envenoming cases,
64 of the 75 patients (85%) had abnormal
results within 12 hours (Box 4, B). The
median time to an abnormality (laboratory
test result or neurological examination) was
1.75 hours (range, 20 min – 33 h 30 min)
for severe envenoming and 2.1 hours
(15 min – 30 h 45 min) for minor envenom-
ing.
DISCUSSION
This study suggests that the combination of
tests for INR, aPTT and CK level and serial
neurological examinations is able to reliably
detect envenomed patients within 12 hours.
No single test was sufficiently useful to
exclude severe envenoming within 12
hours, and a combination of the three tests,
which are relevant to different envenoming
syndromes, was most appropriate. The
study supports an observation period of 12
hours for suspected snakebite, with repeat
laboratory testing and neurological assess-
ments performed on admission and at 6
hours and 12 hours after the bite (Box 5).
Although PBI were used for most patients
and may have delayed the onset of envenom-
ing in some, the majority had evidence of
envenoming on admission despite the use of
PBI. Current recommendations are that repeat
blood tests should be performed 1 hour after
PBI removal because envenoming can develop
rapidly after removal of effective PBI.14
Most literature suggests that only 5% to
10% of snakebite patients develop severe
envenoming,1,3,8,15-19 so much of the emer-
gency department or hospital workload is
the assessment of suspected snakebite to
exclude severe envenoming. This study pro-
vides an approach to assessing these patients
based on a large number of severely enven-
omed patients. Coagulation studies were the
most useful early laboratory parameters
(Box 4, A) because the major clinical syn-
drome was VICC. The aPTT was an early
detector of myotoxicity because of the pres-
ence of an anticoagulant coagulopathy in
black snake envenoming and of VICC in
tiger snake and taipan envenoming — the
snake types that most often cause myotoxic-
ity. CK level was not a good early detector of
myotoxicity and in some cases took over 12
hours to become abnormal in affected
patients, although this was often due to
delayed repeat CK testing (Box 4, A).
The WCC and lymphocyte count were
less useful as early detectors of envenoming
because, unlike VICC and myotoxicity,
where the INR and CK level, respectively,
must become abnormal by definition, this is
not the case for WCC, which remained
4 Plots of the proportion of envenomed patients with normal laboratory test 
results versus time after bite
A: Proportions of patients with: a normal international normalised ratio (INR) in venom-induced 
consumption coagulopathy (VICC); a normal creatine kinase (CK) level in myotoxicity; a normal 
activated partial thromboplastin time (aPTT) in myotoxicity; a normal neurological examination 
in isolated neurotoxicity; and a normal white cell count (WCC) in severe envenoming. 
B: Proportions of patients with normal results of INR, aPTT and CK tests or a normal neurological 
examination, in severe envenoming and minor envenoming. ◆
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some patients with severe envenoming. In
this study, an abnormal WCC only identified
one further case of severe envenoming that
was not detected within 12 hours by the
other tests (Box 3), and it is likely that if a
CK level had been tested at 12 hours in this
patient, it would have been abnormal. The
WCC did not reflect severity of envenoming
and was more often raised in cases of red-
bellied black snake envenoming, which did
not commonly cause severe envenoming,
compared with brown snake envenoming,
which did commonly cause severe enven-
oming with VICC. The WCC was therefore
not included with the three laboratory tests
we selected to identify whether envenoming
had occurred.
There are a number of limitations of this
study, including a greater proportion of
envenomed patients than would be repre-
sentative of normal practice. However, our
focus was on identifying early development
of an abnormal blood test result to indicate
envenoming (“sensitivity”), which is
unlikely to be affected by this. However,
using our suggested approach means that
some patients who do not have envenoming
will be kept in hospital if they have an
abnormal laboratory test result. This most
commonly occurs for CK; 15% of non-
envenomed patients in this study who had
their CK level measured within 6 hours had
an abnormal result. Using our approach,
these patients would be observed in hospital
until it is clear they do not have venom-
induced myotoxicity and their CK level is
seen to be decreasing rather than increasing
over time.
The approach to specific treatment once
an abnormal laboratory test result occurs is
complex and beyond the scope of this study,
which simply answers the initial assessment
question of whether the patient is enven-
omed and, importantly, when clinicians can
be confident that envenoming will not
occur.
Another problem is that there were few
cases of myotoxicity (33) and isolated neu-
rotoxicity (9) in our study. These syndromes
are a major source of delayed or missed
envenoming, so larger studies of these
groups are needed to confirm our approach
in such cases. In addition, modification to
the assessment pathway proposed in Box 5
may be needed for geographical regions
with venomous snake fauna not well repre-
sented in our dataset.
Additionally, although a standardised
series of blood tests was suggested for all
patients recruited to ASP (at admission, 1
hour after release of first aid, and 6 hours
and 12 hours after the bite), this did not
5 Suggested clinical pathway for observation and blood testing of patients with suspected snakebite*
INR =international normalised ratio. aPTT= activated partial thromboplastin time. CK =creatine kinase. VDK= Venom Detection Kit (CSL Ltd, Melbourne, Vic). *Some 
geographical regions with different venomous snake fauna are not well represented in our dataset, and local modification of this pathway may be needed to account for 
differences in snake fauna. † D-dimer test may need repeating if it is moderately elevated (ie, greater than assay cut-off but less than 10 times the cut-off) because this is more 
likely to be a false positive. ‡ A bite-site swab should be collected and stored, but only tested if there is envenoming. § Applicable guidelines at treatment site. ¶ Signs of 
neurotoxicity can be subtle and it is important to include both looking for ptosis and assessing for fatigue (eg, eyelid droop from failure to maintain an upward gaze). ◆
CLINICAL PATHWAY Patient Sticker
SUSPECTED AND CONFIRMED SNAKEBITE: all patients should be observed and have serial blood testing conducted for 
12 hours to exclude severe envenoming, using the following pathway.
Date ___________________________ Signature ____________________________________ Initial for YES
INTERVENTION / OUTCOME INITIAL
Patient presented at _________ hours with/without pressure bandage in situ
Pathology samples taken on admission for:
Coagulation tests (INR, aPTT, D-dimer†); full blood count; urea, electrolytes and creatinine; CK; and VDK‡
Pathology results reviewed within 1 hour and within normal limits
IF pathology results are abnormal, exit pathway, admit patient and treat; see guidelines§
Remove pressure bandage with immobilisation if present, observe for any symptoms
If pressure bandage removed, repeat blood tests 1 hour after removal:
Coagulation tests (INR, aPTT) and CK
Pathology results reviewed and within normal limits
The patient has no signs of neurotoxicity¶ (ptosis, bulbar signs, respiratory or distal paralysis)
IF pathology results are abnormal OR neurotoxicity develops, exit pathway, admit patient and treat; see guidelines§
Repeat blood tests 6 hours after bite (unless already > 6 hours):
Coagulation tests (INR, aPTT) and CK
Pathology results reviewed and within normal limits
The patient has no signs of neurotoxicity¶
IF pathology results are abnormal OR neurotoxicity develops, exit pathway, admit patient and treat; see guidelines§
Final blood tests 12 hours after bite:
Coagulation tests (INR, aPTT) and CK
Pathology results reviewed and within normal limits
The patient has no signs of neurotoxicity¶
IF pathology results are abnormal OR neurotoxicity develops, exit pathway, admit patient and treat; see guidelines§
Patient discharged with normal INR, aPTT and CK  at __________ hoursMJA • Volume 193 Number 5 • 6 September 2010 289
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undertook a conservative analysis because
we assumed that a test result was normal
until the first abnormal test result occurred.
In the case of VICC, the latest normal INR
was at 3 hours and 45 minutes, compared
with the latest abnormal INR at 10 hours
and 30 minutes. This apparent delay of over
10 hours until an abnormal INR is more
likely due to a delay before the next INR test
was done, rather than the INR actually
remaining normal for an additional 6 hours.
Another limitation was the definition of
non-envenoming, which was based on
patients having no clinical effects and nor-
mal blood test results on discharge, which
may have been soon after 12 hours in some
cases. There is a possibility that some of
these patients developed envenoming after
discharge. However, Box 4, B suggests that
the proportion of patients developing
abnormal test results after 12 hours would
be negligible. In addition, if patients re-
presented to hospital with delayed onset of
envenoming, this would have been identi-
fied in the ASP database by additional labo-
ratory tests being ordered.
Further, we used a definition of “clinical”
envenoming, based on whether treatment
was required, and venom concentrations
were not measured to confirm envenoming.
Although the presence of circulating venom
may be the literal interpretation of enven-
oming, ultimately a clinical definition is
more useful, and this is why we focused on
envenoming defined by clinical severity.
In conclusion, in this series of snakebite
patients, the combination of INR, aPTT and
CK level, together with repeated neurologi-
cal assessments, detected all but two cases of
severe envenoming within 12 hours. Most
cases of severe envenoming (96%) were
identified at 6 hours using this combination
of tests. The results of this study can be used
to develop potential clinical pathways, such
as that shown in Box 5. However, such
protocols need to be tested in a prospective
study of patients with suspected snakebite.
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